Wellness company Medifast (NYSE: MED) will be announcing earnings results this Monday after market hours. Here’s what to look for.

Medifast beat analysts’ revenue expectations by 3.7% last quarter, reporting revenues of $105.6 million, down 37.4% year on year. It was a strong quarter for the company, with a beat of analysts’ EPS estimates and a solid beat of analysts’ EBITDA estimates.

Is Medifast a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Medifast’s revenue to decline 36% year on year to $89.7 million, improving from the 40.6% decrease it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.36 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Medifast has only missed Wall Street’s revenue estimates once since going public and has exceeded top-line expectations by 1.6% on average.

Looking at Medifast’s peers in the consumer staples segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Estée Lauder delivered year-on-year revenue growth of 3.6%, beating analysts’ expectations by 2.9%, and USANA reported revenues up 6.7%, in line with consensus estimates. Estée Lauder’s stock price was unchanged after the resultswhile USANA was down 1.5%.

Read our full analysis of Estée Lauder’s results here and USANA’s results here.

Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the consumer staples stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 7.2% on average over the last month. Medifast is down 14.1% during the same time and is heading into earnings with an average analyst price target of $15 (compared to the current share price of $12.02).

P.S. STOP buying the AI stocks everyone’s talking about. The real money? It’s in the profitable pick nobody’s watching yet. We’ve identified an AI profit machine that’s flying under Wall Street’s radar—for now. We can’t keep this research public forever—grab your FREE copy before we pull it offline. GO HERE NOW.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.